The COUPLET study (118) is a Phase Ib clinical trial designed to evaluate the combination of rucaparib, a PARP inhibitor (PARPi), and atezolizumab, an immune checkpoint inhibitor (ICI) targeting PD-L1, in patients with advanced ovarian cancer. Here, PARP1 is linked to ovarian carcinoma.